血清学检测对早期胃癌筛查的临床价值
Clinical Value of Serology in Early Gastric Cancer Screening
DOI: 10.12677/ACM.2022.126786, PDF,   
作者: 沈显亮*：青海大学医学院，青海 西宁；骆玉霜：青海大学附属医院肿瘤内科，青海 西宁；韩玉芳：青海大学附属医院体检中心，青海 西宁
关键词: 血清学检测；早期胃癌；筛查；Serological Detection； Early Gastric Cancer； Screening
摘要: 胃癌是高发病率和死亡率的恶性肿瘤之一。胃癌患者的预后主要与其确诊时所处的临床分期密切相关，早期胃癌患者的治愈率较高，其治疗后5年生存率可达90%，然而目前中国早期胃癌的诊断率仍非常低。由于早期胃癌患者症状不典型，发现时已是进展期或存在转移，造成患者治疗的延误，影响治疗效果。因此，早发现、早治疗对于提高患者的预后水平是必不可少的，而目前血清学检测具有简便、易行、无创、依存性好等优势，在胃癌的早期筛查及早期诊断中发挥着重要作用。目前，血清学检测因其优势已被广泛应用于早期胃癌的筛查。本篇就血清学检查在胃癌筛查中的运用情况加以综述。
Abstract: Gastric cancer is one of the malignant tumors with high morbidity and mortality. The prognosis of patients with gastric cancer is mainly related to the stage in which the disease is diagnosed. The 5-year survival rate of early gastric cancer after treatment can exceed 90%, but the diagnosis rate of early gastric cancer in China is still very low at present. Because the symptoms of patients with early gastric cancer are not obvious, it has reached the late stage when it is discovered, which caus-es the delay of treatment and affects the treatment effect. Therefore, early detection and early treatment are very important to improve the prognosis of patients. At present, serological detection has the advantages of simplicity, feasibility, non-invasion and highly dependence, and plays an im-portant role in early screening and early diagnosis of gastric cancer. In recent years, serological de-tection has become a new hot spot in the screening and diagnosis of gastric cancer. This article re-views the application of serological detection in gastric cancer screening.
文章引用：沈显亮, 骆玉霜, 韩玉芳. 血清学检测对早期胃癌筛查的临床价值[J]. 临床医学进展, 2022, 12(6): 5426-5433. https://doi.org/10.12677/ACM.2022.126786

参考文献

[1] Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. [Google Scholar] [CrossRef] [PubMed]
[2] Hitoshi, K., Takashi, I., Kohei, A., Isobe, Y., Miyashiro, I., Oda, I., et al. (2018) Five-Year Survival Analysis of Surgically Resected Gastric Cancer Cases in Japan: A Retrospective Analysis of More Than 100,000 Patients from the Nationwide Registry of the Japanese Gastric Cancer Association (2001-2007). Gastric Cancer, 21, 144-154. [Google Scholar] [CrossRef] [PubMed]
[3] Sumiyama, K. (2017) Past and Current Trends in Endoscopic Di-agnosis for Early Stage Gastric Cancer in Japan. Gastric Cancer, 2, 20-27. [Google Scholar] [CrossRef] [PubMed]
[4] Fariborz, M., Farahnaz, J., Yaghoub, R. and Tolou, H. (2014) Screening of Precancerous Gastric Lesions by Serum Pepsinogen, Gastrin-17, Anti-Helicobacter Pylori and Anti-CagA Antibodies in Dyspeptic Patients over 50 Years Old in Guilan Province, North of Iran. Asian Pacific Journal of Cancer Prevention, 15, 7635-7638. [Google Scholar] [CrossRef] 
[5] 朱春平, 赵建业, 申晓军, 钱维, 马颖才, 张硕, 等. 血清胃泌素-17联合胃蛋白酶原检测对胃癌诊断价值的多中心临床研究[J]. 中华消化内镜杂志, 2017, 34(1): 19-23.
[6] 李梦颖, 张德庆, 陆绚, 陈卫昌. 两种血清学方法在胃癌及其癌前状态筛查中的价值[J]. 中华内科杂志, 2018, 57(12): 907-911.
[7] Bang, C.S., Lee, J.J. and Baik, G.H. (2019) Diagnostic Performance of Serum Pepsin-ogen Assay for the Prediction of Atrophic Gastritis and Gastric Neoplasms: Protocol for a Systematic Review and Me-ta-Analysis. Medicine, 98, Article ID: e14240. [Google Scholar] [CrossRef] 
[8] Weiwei, Z., Shuxiang, Z., Lei, Y., Wei, W., Gao, J., Guo, N., et al. (2020) Serum MiR-101-3p Combined with Pepsinogen Contrib-utes to the Early Diagnosis of Gastric Cancer. BMC Medical Genetics, 21, Article No. 28. [Google Scholar] [CrossRef] [PubMed]
[9] Kazumasa, M. (2006) Gastric Cancer Screening Using the Serum Pepsinogen Test Method. Gastric Cancer, 9, 245-253. [Google Scholar] [CrossRef] [PubMed]
[10] Osumi, H., Fujisaki, J., Suganuma, T., Horiuchi, Y., Omae, M., Yoshio, T., et al. (2017) A Significant Increase in the Pepsinogen I/II Ratio Is a Reliable Biomarker for Successful Heli-cobacter Pylori Eradication. PLOS ONE, 12, Article ID: e0183980. [Google Scholar] [CrossRef] [PubMed]
[11] Kim, N. and Jung, H.C. (2010) The Role of Serum Pepsinogen in the Detection of Gastric Cancer. Gut Liver, 4, 307-319. [Google Scholar] [CrossRef] [PubMed]
[12] Shulkes, A. and Baldwin, G. (2001) Biology and Pathology of Non-Amidated Gastrins. Scandinavian Journal of Clinical and La-boratory Investigation, 234, 123-128. [Google Scholar] [CrossRef] 
[13] Sun, L., Tu, H., Liu, J., Gong, Y., Xu, Q., Jing, J., et al. (2014) A Comprehensive Evaluation of Fasting Serum Gastrin-17 as a Predictor of Diseased Stomach in Chinese Population. Scandinavian Journal of Gastroenterology, 49, 1164-1172. [Google Scholar] [CrossRef] [PubMed]
[14] 陈莫耶, 徐倩, 孙丽萍, 孙明军. 血清胃泌素17水平与胃癌及癌前疾病的相关性研究[J]. 胃肠病学和肝病学杂志, 2015, 24(2): 161-165.
[15] Li, Y., Zhao, Y., Li, Y., Zhang, X., Li, C., Long, N., et al. (2021) Gastrin-17 Induces Gastric Cancer Cell Epithelial-Mesenchymal Transition via the Wnt/β-Catenin Signaling Pathway. Journal of Physiology and Biochemistry, 77, 93-104. [Google Scholar] [CrossRef] [PubMed]
[16] Hooi, J., Lai, W.Y., Ng, W.K., Suen, M.M.Y., Underwood, F.E., Tanyingoh, D., et al. (2017) Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. Gastroenterology, 153, 420-429. [Google Scholar] [CrossRef] [PubMed]
[17] Guo, Y., Zhang, Y., Gerhard, M., Gao, J.J., Mejias-Luque, R., Zhang, L., et al. (2020) Effect of Helicobacter Pylori on Gastrointestinal Microbiota: A Population-Based Study in Linqu, a High-Risk Area of Gastric Cancer. Gut, 69, 1598-1607. [Google Scholar] [CrossRef] [PubMed]
[18] Zhang, L., Ren, J., Pan, K., Ma, J., Li, J., Shen, L., et al. (2010) Detection of Gastric Carcinoma-Associated MG7-Ag by Serum Immuno-PCR Assay in a High-Risk Chinese Population, with Implication for Screening. International Journal of Cancer, 126, 469-473. [Google Scholar] [CrossRef] [PubMed]
[19] Zongyue, Z., Sheng, F., Ping, H., Zhao, L., Zhang, H., Tang, X., et al. (2014) The Diagnostic Value of Monoclonal Gastric Cancer 7 Antigen: A Systematic Review with Meta-Analysis. Clinical and Experimental Medicine, 14, 337-343. [Google Scholar] [CrossRef] [PubMed]
[20] 杨枫, 王晓玲, 邬虹娇, 孙晓兰, 陈敏. 血清肿瘤标志物水平与胃癌的关系研究[J]. 中国肿瘤临床与康复, 2022, 29(3): 265-268.
[21] 韩梅, 连俊, 马明杰, 喇琴, 张辉. 血清胃蛋白酶原与肿瘤标志物CEA、CA199、CA242、CA724联合检测对胃癌诊断的价值分析[J]. 河北医药, 2019, 41(23): 3574-3577.
[22] 刘忆华, 成善泉, 漆晴, 彭清烨, 郑安斌. CEA、AFP和CA242在胃癌病理诊断及预后评估中的作用[J]. 河北医药, 2017, 39(9): 1335-1337.
[23] 孙会, 祝丽晶, 王正前. 血清肿瘤标志物联合检测对胃癌的诊断价值[J]. 中国当代医药, 2020, 27(21): 4-7+封3.
[24] 杨莉, 李晓南, 杨晓雪. 血清肿瘤标志物CEA、CA19-9及CA724联合检测在胃癌诊断中的价值分析[J]. 临床和实验医学杂志, 2020, 19(4): 387-391.
[25] Feng, F., Tian, Y., Xu, G., Liu, Z., Liu, S., Zheng, G., et al. (2017) Diagnostic and Prognostic Value of, C.E.A., CA19-9, AFP and CA125 for Early Gastric Cancer. BMC Cancer, 17, Article No. 737. [Google Scholar] [CrossRef] [PubMed]
[26] Hideaki, S., Tamaki, N., Manabu, O., Koji, O. and Yutaka, T. (2014) Clinical Significance of Serum Tumor Markers for Gastric Cancer: A Systematic Review of Literature by the Task Force of the Japanese Gastric Cancer Association. Gastric Cancer, 17, 26-33. [Google Scholar] [CrossRef] [PubMed]
[27] 蔡晓娟, 王堃, 喻晶. 异常凝血酶原联合CEA、CA72-4和CA199在胃癌诊治中的价值[J]. 肿瘤防治研究, 2018, 45(6): 395-399.
[28] Song, X.H., Liu, K., Yang, S.J., Zhang, W.-H., Chen, X.-L., Zhao, L.-Y., et al. (2020) Prognostic Value of Changes in Preoperative and Postoperative Serum CA19-9 Levels in Gastric Cancer. Frontiers in Oncology, 10, Article No. 1432. [Google Scholar] [CrossRef] [PubMed]
[29] 李湘英. 肿瘤标志物联合检测在消化道恶性肿瘤中的应用[J]. 国际检验医学杂志, 2012, 33(19): 2415-2417.
[30] 杨剑, 万成乐, 金雷. CA72-4、CA19-9、CA125、CA50医学参考值范围及其对胃癌早期诊断价值的研究[J]. 分子诊断与治疗杂志, 2021, 13(7): 1150-1153.
[31] 廖专, 孙涛, 吴浩, 杨帆, 邹文斌. 中国早期胃癌筛查及内镜诊治共识意见(2014年, 长沙) [J]. 中华消化杂志, 2014, 34(7): 433-448.
[32] Miki, K. (2011) Gastric Cancer Screening by Combined Assay for Serum Anti-Helicobacter Pylori IgG Antibody and Serum Pepsinogen Levels—“ABC Method”. Proceedings of the Japan Academy, Series B, Physical and Biological Sciences, 87, 405-14. [Google Scholar] [CrossRef] [PubMed]
[33] 冯慧. 上消化道早癌筛查、诊断及其相关技术的探索性研究[D]: [博士学位论文]. 合肥: 安徽医科大学, 2016.
[34] 周玉梅. 血清胃蛋白酶原比值联合胃泌素-17在早期胃癌诊断中的临床价值[J]. 临床医药文献电子杂志, 2019, 6(90): 132+134.
[35] 杜奕奇, 蔡全才, 廖专, 方军, 朱春平, 等. 中国早期胃癌筛查流程专家共识意见(草案) (2017年, 上海) [J]. 胃肠病学, 2018, 23(2): 92-97.
[36] 高福利, 钱建清, 徐晓丹, 王卫军, 刘罗杰. 新型胃癌评分系统在早期胃癌筛查中的应用[J]. 中国实用医刊, 2020, 47(16): 6-9.
[37] 倪栋琼, 吕宾, 包海标, 金海峰, 赵晶, 徐毅, 等. 不同血清学危险分层方法在人群早期胃癌筛查中的比较研究[J]. 中华内科杂志, 2019, 58(4): 294-300.
[38] 文采, 肖明娜, 朴善英. PG、MG7-Ag联合G-17检测对胃癌前病变、胃癌的诊断及鉴别诊断[J]. 分子诊断与治疗杂志, 2020, 12(11): 1488-1492.
[39] 孟培, 龙拥军, 戴平, 王坤. 联合检测血清抗HpAb、胃泌素-17和MG7-Ag对胃癌诊断的临床意义[J]. 标记免疫分析与临床, 2019, 26(2): 216-219.
[40] Lin, Z., Bian, H., Chen, C., Chen, W. and Li, Q. (2021) Application of Serum Pepsinogen and Carbohydrate Antigen 72-4 (CA72-4) Combined with Gastrin-17 (G-17) Detec-tion in the Screening, Diagnosis, and Evaluation of Early Gastric Cancer. Journal of Gastrointestinal Oncology, 12, 1042-1048. [Google Scholar] [CrossRef] [PubMed]
[41] 庄伟, 计钰亮, 朱婷婷. 早期胃癌胃镜筛查中联合应用血清PG、G-17、CA72-4及Hp检测的价值研究[J]. 浙江医学, 2020, 42(14): 1529-1532.
[42] 王晓阳, 谢爱敏, 郎少磊. CA72-4、CA19-9、CEA在胃癌诊断及预后评价中的应用价值[J]. 哈尔滨医药, 2020, 40(6): 555-557.
[43] 刘彦合, 宋杰峰, 李慧, 叶晓谊, 曾祥勇. 血清肿瘤标志物CEA、CA19-9、CA242及CA724联合检测在胃癌诊断中的价值分析[J]. 现代消化及介入诊疗, 2019, 24(4): 416-420.

为你推荐